FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Articles|May 18, 2022
Daily Medication Pearl: Simeprevir (Olysio)
Author(s)Saro Arakelians, PharmD
:Simeprevir (Olysio) is an NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen.
Advertisement
Medication Pearl of the Day: Simeprevir (Olysio)
Indication: Simeprevir (Olysio) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
Insight:
- Dosing:One capsule taken once daily with food.
- Dosage forms: Capsule 150 mg.
- Adverse events: The most common reported adverse reactions (greater than 20% of subjects) in subjects receiving the combination of simeprevir with peginterferon and ribavirin and occurring with at least 3% higher frequency compared to subjects receiving placebo in combination with peginterferon alfa and ribavirin during the first 12 weeks of treatment were rash (including photosensitivity), pruritus, and nausea.
- Mechanism of action: Simeprevir is an inhibitor of the HCV NS3/4A protease, which is essential for viral replication. In a biochemical assay, simeprevir inhibited the proteolytic activity of recombinant genotype 1a and 1b HCV NS3/4A proteases, with median Ki values of 0.5 nM and 1.4 nM, respectively.
- Manufacturer: Janssen Therapeutics
Source
Advertisement
Related to this article
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
Advertisement
Advertisement